Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the health-check domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/u347700914/domains/themoneyoffice.com/public_html/wp-includes/functions.php on line 6121

WordPress database error: [Table 'u347700914_MNO.TM_actionscheduler_actions' doesn't exist]
SELECT a.action_id FROM TM_actionscheduler_actions a LEFT JOIN TM_actionscheduler_groups g ON g.group_id=a.group_id WHERE 1=1 AND g.slug='image-optimization/cleanup' AND a.hook='image-optimization/cleanup/stuck-operation' AND a.args='[]' AND a.status IN ('pending') ORDER BY a.scheduled_date_gmt ASC LIMIT 0, 1

WordPress database error: [Table 'u347700914_MNO.TM_actionscheduler_groups' doesn't exist]
SELECT group_id FROM TM_actionscheduler_groups WHERE slug='image-optimization/cleanup'

WordPress database error: [Table 'u347700914_MNO.TM_actionscheduler_groups' doesn't exist]
SHOW FULL COLUMNS FROM `TM_actionscheduler_groups`

WordPress database error: [Table 'u347700914_MNO.TM_actionscheduler_actions' doesn't exist]
INSERT INTO TM_actionscheduler_actions ( `hook`, `status`, `scheduled_date_gmt`, `scheduled_date_local`, `schedule`, `group_id`, `priority`, `args` ) SELECT 'image-optimization/cleanup/stuck-operation', 'pending', '2025-06-27 11:09:40', '2025-06-27 12:09:40', 'O:32:\"ActionScheduler_IntervalSchedule\":5:{s:22:\"\0*\0scheduled_timestamp\";i:1751022580;s:18:\"\0*\0first_timestamp\";i:1751022580;s:13:\"\0*\0recurrence\";i:300;s:49:\"\0ActionScheduler_IntervalSchedule\0start_timestamp\";i:1751022580;s:53:\"\0ActionScheduler_IntervalSchedule\0interval_in_seconds\";i:300;}', 0, 10, '[]' FROM DUAL WHERE ( SELECT NULL FROM DUAL ) IS NULL

WordPress database error: [Table 'u347700914_MNO.TM_actionscheduler_actions' doesn't exist]
SELECT a.action_id FROM TM_actionscheduler_actions a WHERE 1=1 AND a.hook='action_scheduler/migration_hook' AND a.status IN ('in-progress') ORDER BY a.scheduled_date_gmt ASC LIMIT 0, 1

WordPress database error: [Table 'u347700914_MNO.TM_actionscheduler_actions' doesn't exist]
SELECT a.action_id FROM TM_actionscheduler_actions a WHERE 1=1 AND a.hook='action_scheduler/migration_hook' AND a.status IN ('pending') ORDER BY a.scheduled_date_gmt ASC LIMIT 0, 1

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update – All about Money

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Biopharma Corporation

Arbutus Biopharma Corporation

WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its first quarter 2024 financial results and corporate update for Thursday, May 2, 2024. The schedule for the press release and conference call/webcast are as follows:

•

Q1 2024 Press Release:

Thursday, May 2, 2024 at 7:30 a.m. ET

•

Q1 2024 Conference Call/Webcast:

Thursday, May 2, 2024 at 8:45 a.m. ET

 

 

 

To dial-in for the conference call by phone, please register using the following link: Registration Link. A live webcast of the conference call can be accessed through the Investors section of Arbutus’ website at www.arbutusbio.com.

An archived webcast will be available on the Arbutus website after the event.

About Arbutus

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729) and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com

Share this article